0.75
+0.025(+3.47%)
Currency In USD
| Previous Close | 0.72 |
| Open | 0.72 |
| Day High | 0.76 |
| Day Low | 0.71 |
| 52-Week High | 6.06 |
| 52-Week Low | 0.69 |
| Volume | 270,529 |
| Average Volume | 237,924 |
| Market Cap | 28.54M |
| PE | -3.55 |
| EPS | -0.21 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.83 |
| Change | 0.03 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $42.62 as of June 25, 2025 at a share price of $0.746. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $322.9 as of June 25, 2025 at a share price of $0.746.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
GlobeNewswire Inc.
Jun 16, 2025 8:35 PM GMT
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics to Present at the BIO International Convention 2025
GlobeNewswire Inc.
Jun 16, 2025 1:50 PM GMT
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
GlobeNewswire Inc.
Jun 09, 2025 12:30 PM GMT
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growthHOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage bio